Literature DB >> 1364851

Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies.

F J Hock1, K Wirth, U Albus, W Linz, H J Gerhards, G Wiemer, S Henke, G Breipohl, W König, J Knolle.   

Abstract

1. Hoe 140 (D-Arg-[Hyp3, Thi5, D-Tic7, Oic8]bradykinin) is a new bradykinin (BK)-antagonist. It was tested in several in vitro assays and compared with D-Arg-[Hyp2,Thi5,8,D-Phe7]BK. 2. In receptor binding studies in guinea-pig ileum preparations, Hoe 140 showed an IC50 of 1.07 x 10(-9) mol l-1 and a KI value of 7.98 x 10(-10) mol l-1. 3. In isolated organ preparations Hoe 140 and D-Arg-[Hyp2,Thi5,8, D-Phe7]BK inhibited bradykinin-induced contractions concentration dependently, with IC50-values in the guinea-pig ileum preparation of 1.1 x 10(-8) mol l-1 and 3 x 10(-5) mol l-1, respectively. pA2 values in this tissue were 8.42 and 6.18, respectively. In the rat uterus preparation the IC50 value was 4.9 x 10(-9) mol l-1 for Hoe 140. D-Arg-[Hyp2, Thi5,8, D-Phe7]BK showed an IC50 of 4.0 x 10(-6) mol l-1. The IC50 values in the guinea-pig isolated pulmonary artery were 5.4 x 10(-9) mol l-1 and 6.4 x 10(-6) mol l-1, respectively. In the rabbit aorta no inhibitory effects on Des-Arg9-BK induced contractions were observed. 4. In cultured bovine endothelial cells, Hoe 140 antagonized (IC50 = 10(-8) mol l-1) bradykinin-induced endothelium-derived relaxing factor (EDRF) release and the bradykinin-induced increase in cytosolic free calcium (IC50 = 10(-9) mol l-1). 5. Hoe 140 (10 -7mol I1) totally suppressed the bradykinin-induced (10 8 to 10- mol I') prostacyclin (PGI2) release from cultured endothelial cells of bovine aorta. D-Arg-[Hyp2, Thi5'8, D-Phe7]BK (10- 7 mol I1- ) showed a weaker antagonism. 6. Taken together these results show that Hoe 140 is a highly potent bradykinin antagonist. It was two to three orders of magnitude more potent than D-Arg-[Hyp2, Thi5 8, D-Phe7]BK.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1364851      PMCID: PMC1917958          DOI: 10.1111/j.1476-5381.1991.tb12248.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters.

Authors:  J M VAN ROSSUM
Journal:  Arch Int Pharmacodyn Ther       Date:  1963

Review 2.  New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization.

Authors:  D Regoli; N E Rhaleb; S Dion; G Drapeau
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

3.  Suppression of carrageenan-induced hyperalgesia, hyperthermia and edema by a bradykinin antagonist.

Authors:  A H Costello; K M Hargreaves
Journal:  Eur J Pharmacol       Date:  1989-11-21       Impact factor: 4.432

4.  Action of peptides and other algesic agents on paravascular pain receptors of the isolated perfused rabbit ear.

Authors:  H Juan; F Lembeck
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

5.  Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions.

Authors:  L R Steranka; D C Manning; C J DeHaas; J W Ferkany; S A Borosky; J R Connor; R J Vavrek; J M Stewart; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

6.  Two bradykinin binding sites with picomolar affinities.

Authors:  D C Manning; R Vavrek; J M Stewart; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1986-05       Impact factor: 4.030

7.  Stimulation of arachidonic acid metabolism in rat kidney mesangial cells by bradykinin, antidiuretic hormone, and their analogues.

Authors:  A Uglesity; J I Kreisberg; L Levine
Journal:  Prostaglandins Leukot Med       Date:  1983-01

8.  Converting enzyme inhibition and vascular prostacyclin synthesis: effect of kinin receptor antagonism.

Authors:  G Hoffmann; R Pietsch; B O Göbel; B Weisser; G Bönner; H Vetter; R Düsing
Journal:  Eur J Pharmacol       Date:  1990-03-13       Impact factor: 4.432

Review 9.  Antagonists of B2 bradykinin receptors.

Authors:  L R Steranka; S G Farmer; R M Burch
Journal:  FASEB J       Date:  1989-07       Impact factor: 5.191

10.  Effect of bradykinin antagonists on bradykinin-induced plasma extravasation, venoconstriction, prostaglandin E2 release, nociceptor stimulation and contraction of the iris sphincter muscle in the rabbit.

Authors:  T Griesbacher; F Lembeck
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

View more
  139 in total

Review 1.  Therapeutic approaches in hereditary angioedema.

Authors:  Sabina Antonela Antoniu
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

2.  Inhibition of kinin breakdown prolongs retention and action of bradykinin in a myocardial B2 receptor compartment.

Authors:  Andreas Dendorfer; Verena Folkers; Matthias Klinger; Sebastian Wolfrum; Peter Dominiak
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

Review 3.  Bradykinin and asthma.

Authors:  P J Barnes
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

Review 4.  Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients.

Authors:  Henriette Farkas
Journal:  Paediatr Drugs       Date:  2018-04       Impact factor: 3.022

5.  Bradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow.

Authors:  Sigurdur T Sigurdsson; Olaf B Paulson; Arne Høj Nielsen; Svend Strandgaard
Journal:  J Cereb Blood Flow Metab       Date:  2013-12-11       Impact factor: 6.200

6.  Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas.

Authors:  Weiping Zhang; Neil Bhola; Shailaja Kalyankrishna; William Gooding; Jennifer Hunt; Raja Seethala; Jennifer R Grandis; Jill M Siegfried
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

7.  Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium.

Authors:  Bikramjit Chopra; Stacey R Barrick; Susan Meyers; Jonathan M Beckel; Mark L Zeidel; Anthony P D W Ford; William C de Groat; Lori A Birder
Journal:  J Physiol       Date:  2004-12-02       Impact factor: 5.182

8.  A study of the action of bradykinin and bradykinin analogues in the human nasal airway.

Authors:  C E Austin; J C Foreman
Journal:  J Physiol       Date:  1994-07-15       Impact factor: 5.182

9.  Bradykinin binding sites in healthy and carcinomatous human lung.

Authors:  A Trifilieff; E Lach; P Dumont; J P Gies
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

10.  Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents.

Authors:  Steeve Houle; Martin D Papez; Mara Ferazzini; Morley D Hollenberg; Nathalie Vergnolle
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.